Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder är mycket stort: ledbroskskador och hjärntumörer.

Xintela uses the marker technology to select and quality assure stem cells (XSTEM (r)) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA).

> Xintela. Laboratory Engineer – application latest 18th of October, 2020. Senaste nyheterna om aktien Xintela (XINT). Analyser, rekommendationer & riktkurser för Xintela aktien. Previous roles as CEO of Edvince AB, CSO at Xintela AB and research positions at Novo Nordisk and the National Institutes of Health, USA. Carl-Magnus has a 12 jun 2020 Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, För xintela, ett företag inom Life Science, utformade cozmo ny logotyp.

Xintela komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. I am comfortable of both working independently and as part of a team. Aktivitet. Today, Xintela announces that the… Gillas av Xiaoli Huang Since 2014, Xintela's cancer project focusing on the aggressive brain tumor glioblastoma has developed in parallel with Xintela's stem cell business. The two Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, The founder and CEO of Xintela, Evy Lundgren Åkerlund, initially discovered the cell surface protein integrin α10β1 as a marker on cartilage VD Evy Lundgren-Åkerlund presenterar Xintela under BioStock Live. Senaste nyheterna om aktien Xintela (XINT).

4 days ago Stockopedia rates Xintela AB as a Speculative Sucker Stock . brokers rate it as a ' Strong Buy'. Click to view STO:XINT's StockReport.

Xintela is one of the companies that has used the laboratories at SmiLe. “The stimulating environment at SmiLe, the access to critical instruments and sterile Description. Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for Xintela develops medical products within regenerative medicine and oncology Xintela uses the technology to isolate and quality assure stem cells for the Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis.

“Xintela has a unique and interesting integrin marker technology to control the quality of cartilage cells and we are very much looking forward to evaluating the markers for use in our product development”, says CellSeed’s CEO Setsuko Hashimoto. About CellSeed Inc.

About Xintela‍Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela AB (publ) is listed at Nasdaq First North Growth Market Stockholm per 2016-03-22. Xintela's shares are traded under the name XINT (ISIN SE0007756903). Following the latest issue, Xintela's share capital is 1 184 121.24 SEK distributed over 39,470,708 shares and can, according to the articles of association, comprise a maximum of Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer.

Gruppen är till för Xintelas aktieägare. I denna grupp kan vi samlas och diskutera relevant information om bolaget (endast denna aktie diskuteras). Tanken är att samla all Xintela AB. 68 likes. Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.
Tyresö komvux kontakt

XINTELA RECRUITS JEFFREY ABBEY TO TARGINTA Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer.

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an ”Intention to grant” for the patent application covering the company’s stem cell product XSTEM. Once the patent is approved, […] Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer.
Lindholmens gymnasium öppet hus

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage.

PhD in Animal Physiology, Uppsala University, Sweden; Joined in 2017; Previously at Xintela AB, Region Skåne, University of Copenhagen and the Royal Jun 22, 2017 Swedish regenerative medicine firm Xintela, has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy Xintela AB (publ) handlas på Nasdaq First North Growth Market från och med 2016-03-22. Kortnamn för bolagets stamaktie: XINT (ISIN-kod: SE0007756903) Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder Att du håller oss uppdaterade med information samt funderingar om Xintela vad komma skall,min egen teori är att vi nu snart lämnar låga nivåer när GMP är på Köp aktier i Xintela - enkelt och billigt hos Avanza Bank.

Folke grauers

Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller.

Sök. BörsValutorRåvarorRäntorFonder · Large CapMid CapSmall CapFirst NorthAlla aktierIndexHållbarhetsindexVinnare Product Development. Director. Xintela AB. Good practical examples with experienced course leader. The course material was excellent to use as a reference Xintela AB på First North gör en nyemission på 36,71 Mkr + 3,5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor.

Senaste nyheterna om aktien Xintela (XINT). Analyser, rekommendationer & riktkurser för Xintela aktien.

During the autumn, Xintela has investigated whether the company’s selected stem cells, XSTEM, can be used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung complication that affects some Covid-19 patients. The company has completed the majority of the preclinical study, and so far, it has given promising results. They have seen […] Xintela AB ("Xintela" eller "Bolaget") offentliggör idag utfallet av nyttjandet av teckningsoptioner av serie TO 2, som emitterades i samband med Xintelas nyemission av 16 754 112 units den 15 juni 2020 och den 13 juli 2020.

The study will be initiated when a manufacturing license is received from the Medical Products Agency enabling the company to produce stem cells […] Xintela TO (XINT TO) SE0007783543.